Pharma BD Deal Intelligence
Merck's multi-year collaboration to discover molecular glue degraders with Proxygen, a $2.55B biobucks deal against multiple undisclosed targets. A platform bet with no upfront disclosed and no indications named, leaving its real value entirely contingent on future preclinical hits.
Proxygen's separate 2022 strategic collaboration with Merck KGaA (up to EUR495M / ~$554M) - a DIFFERENT company from Merck & Co/MSD. Documented to disambiguate…
Proxygen will receive an upfront payment and be eligible for future payments of up to $2.55 billion.
Proxygen's own milestone timeline. Confirms the April 2023 MSD deal is the only Merck & Co agreement (no post-2023 MSD expansion) and records platform…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Merck entered a multi-year collaboration with Proxygen to discover and develop novel molecular glue degraders against multiple therapeutic targets.
$540M Global TPD Market (2024) · $402M Molecular Glue Degrader Market (2024)
Molecular glue degraders represent a transformative approach to drug discovery by inducing proximity between a target protein and an E3 ubiquitin ligase, leading to selective protein degradation. This technology promises to unlock a large proportion of the undruggable target space and deliver innovative therapies for diseases with high unmet medical need across oncology, immunology, and neuroscience.
Merck & Co (MSD) gains access to Proxygen's scalable molecular glue discovery platform to identify and develop novel degrader programs against multiple undisclosed therapeutic targets, up to a deal potential of $2.55B in milestones plus royalties. This is a new, standalone collaboration with Merck & Co; it is distinct from Proxygen's separate 2022 agreement with Merck KGaA (up to EUR495M / ~$554M), a different company. Proxygen's platform addresses the historical challenge of rational molecular glue design across therapeutic areas.
Merck entered multi-year collaboration for molecular glue degraders against multiple targets.
Proxygen advanced two internal lead programs (a p300 molecular glue degrader and a brain-penetrant CDK12 program) toward clinical development and expanded its platform beyond degradation. Platform-wide progress; specific Merck & Co (MSD) collaboration programs remain undisclosed.
Multiple expanding deals validate Proxygen platform. Pre-clinical stage. Long-term bet on molecular glue degraders.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Proxygen GmbH (this deal) | 2023 | $2.5B | 63 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2023 deals · Merck & Co. Inc. deals